There is still no consensus on the most suitable heart valve replacement for women of childbearing age. Mechanical valves carry a risk of thromboembolism and the need for anticoagulation whereas bioprostheses have a lower thromboembolic risk but are not as durable, particularly in the young. There is controversy about the safest anticoagulant regimen during pregnancy. Early reports of pregnancy in women with mechanical valves were usually of anecdotal cases: they were inspired by disaster rather than by success. Most of these reports came from the United States where overanticoagulation was the rule because of the use of thromboplastins of low responsiveness.' There is still no universal adoption of the International Normalised Ratio (INR) 
in 182 women; 151 pregnancies in 133 women with mechanical valves, and 63 pregnancies in 45 women with bioprostheses. Most women were in New York Heart Association class I or II and in sinus rhythm. .150 women with mechanical valves and 11 (17%) with bioprotheses received anticoagulants during pregnancy. One patient with an aortic valve prosthesis refused to take anticoagulants. Including the spontaneous abortions reported as well as the therapeutic abortions 83% of the pregnancies in women with bioprostheses and 73% in those with mechanical valves resulted in a healthy baby, full term or premature, who did well (NS). The incidencm of stillbirths (3% and 6%) and of reported spontaneous abortions (10% and 12%) did not differ between the two groups. If the spontaneous abortions are excluded (because they are unlikely to have been fully reported), the success rate was 91% for women with bioprosthetic valves and 84% for women with mechanical valves (NS) . 114 Seventeen women with mechanical valves and 10 with bioprostheses had more than one pregnancy (23 women had had two pregnancies, three women had had three, and one had had four pregnancies) all of which were included in this study. Twenty with mechanical valves and seven with bioprostheses had also had more than one (two pregnancies in 25 and three pregnancies in two) details of which were not made available.
Thirteen warfarin throughout pregnancy; one had been treated with heparin for the first trimester and warfarin thereafter. Two of the three therapeutic abortions were performed because of heart failure NYHA class m and IV. There were no embryopathies. One central nervous system abnormality (mental retardation) was recorded, the mother having been treated with intravenous heparin in the first trimester and warfarin thereafter. One baby with congenital adrenal hyperplasia (a recessively inherited condition unrelated to warfarin treatment) has done well. Two babies were not delivered owing to maternal death and there was also one ectopic pregnancy (table 3) . The numbers of healthy babies were similar in the two groups but the incidence of prematurity was significantly lower (p < 0-05) in the bioprosthesis group (table 4) . Table 5 shows the outcome for the babies according to the different anticoagulant regimens. There was no difference in outcome between patients taking no anticoagulant and patients taking heparin for the first trimester and warfarin thereafter, except for a lower incidence of prematurity (p < 0 05). Nor was there any difference in the outcome between patients taking warfarin throughout and patients on heparin throughout. Women taking heparin followed by warfarin were more likely to have a healthy baby than women taking heparin throughout pregnancy (p < 0 05). The incidence of stillbirths was also lower in women taking heparin followed by warfarin than in either women taking warfarin throughout or heparin throughout (p < 0 05).
The outcome for women with multiple pregnancies or multiple valves was comparable with the overall result. (n(%)) (n(%)) (n(%)) (n(%)) thrombolytic agents (two with streptokinase and two with alteplase). Ten of the 13 women with thrombosed valves were taking heparin, two were taking warfarin, and one was not taking anticoagulants (heparin v warfarin p < 0 05). Twelve of the 13 thrombosed valves were mitral and only one was aortic (no anticoagulant). Five of the mitral prostheses were Bj6rk-Shiley, four were StarrEdwards, one was a St Jude, and there were two others. There were eight major embolic events, two fatal (one was associated with valve thrombosis) and six without permanent sequelae. Five women were taking heparin and three warfarin (p < 005). Table 6 shows these thromboembolic complications.
There were seven major bleeding complications needing more than two units of transfused blood, five during pregnancy and two postpartum requiring hysterectomy. Five women were treated with heparin and two with warfarin (p < 0 05).
Of the 34 pregnancies in 29 women with mechanical valves treated with heparin throughout, eight (24%) were complicated by valve thrombosis, four (12%) by embolic events and four (12%) by major bleeding, giving a major complication rate of 48%. There was also one case of severe osteopenia in a woman treated with heparin throughout pregnancy but no thrombocytopenia was reported. Discussion Some regard bioprostheses as the best valves for women with valve disease who wish to have children. This is because treatment with anticoagulants can usually be avoided. Though this was the view of most of the respondents to the questionnaire many of them also indicated that they had no personal experience of pregnancy in a woman with an artificial valve of any sort. Most of the women in this study with a bioprosthesis went through pregnancy successfully without anticoagulant treatment. The fetal outcome was excellent and our data for this group do not differ from the normal population.6 This accords with previous reports.3 [7] [8] [9] The outcome was only slightly less favourable for the babies of mothers with mechanical valves. The difference did not reach statistical significance, except for prematurity. This slight advantage for the babies of mothers with bioprostheses has to be set against the expectation of accelerated valve failure and the need for early reoperation with its mortality and morbidity at a time when both the children and their mothers are still young. More than a third of the young women with a bioprothesis in this study developed primary valve dysfunction and had repeat replacement. Similarly, almost 60% of the bioprotheses failed in the series of Bortolloti et al,'0 and 13% had to be replaced in that of Salazar et al 7-12 months after delivery.4 In another group of 87 women with bioprotheses the incidence of structural valve deterioration and reoperation was 47-1% and 59% for women going through pregnancies v 14-3% and 19% (both p < 005) for those who did not. The mean interval from operation to reoperation was only 72X1 months." Premature valve failure is a well recognised complication of bioprostheses, particularly in young people. It seems that pregnancy can further accelerate this process. Increased calcium turnover is probably the reason: this is blamed for poor durability of bioprostheses in children and calcium turnover will be even higher in pregnancy. Therefore pregnancy is an independent risk factor for very rapid bioprosthetic failure. Because reoperation is technically more difficult and carries an increased risk this grave disadvantage of bioprostheses in young women should not be lightly dismissed. patients who were taking oral anticoagulants in the first trimester. The incidence of embryopathy in other studies varies from 4% to 7.9%,1517 and the risk of malformed neonates has been estimated to be less than 5%.1819 Only one study reports a much higher incidence of up to 29-6% but the abnormalities in these babies were identified by clinical geneticists.'7 Over anticoagulation was likely to increase fetal bleeding complications including haemorrhage into developing cartilaginous bone and embryopathy.20
In our study the fetal outcome did not differ in the groups given warfarin and heparin throughout pregnancy, the reported abortion rate being 22% for each and the stillbirths 9% and 11% respectively. Maternal complications were higher in the women with a mechanical valve than in women with a bioprosthesis but they were nearly all related to heparin treatment. There were 13 valve thromboses of which four were fatal, eight embolic events of which two were fatal, and seven bleeds. Most of these complications occurred in women receiving heparin. This is in agreement with previous studies. Wang et In this a long retrospective study more than half of the pregnancies reported occurred after 1985. The study population is not homogeneous, though most women were young, haemodynamically stable, and had rheumatic heart disease. An important limitation is that we do not have detailed information on the level of anticoagulation on the dose throughout pregnancy. We knew from the questionnaire what was aimed at and considered optimal both for warfarin and heparin but it would have been very time consuming and probably impossible for our colleagues to have obtained all these figures retrospectively. The target for the INR was generally stated to be between 3-0 and 4-0. The target partial thromboplastin time was twice the control value. We do not know whether these targets were reached or the values at the time that complications developed. Anticoagulant control should now be prosthesis specific with lower targets set for second generation mechanical valves and an INR of between 2-0 and 3-0 in pregnancy. 30 Finally, the cases analysed represent the experience only of those cardiologists who took the trouble to provide details of their patients. The data are to that extent selective but otherwise unbiased.
Addendum
Since submission of this paper a further case of valve thrombosis has been notified to us. This was in a 25 year old woman with a HallKaster mechanical mitral prosthesis (29 mm) which thrombosed at 34 weeks' gestation while she was being treated with subcutaneous heparin. Emergency-mitral valve re-replacement was carried out after delivery of the baby by caesarean section. Both mother and child survived.
